An audio replay of the call will be available beginning either on the Teleflex website or by telephone. Teleflex Incorporated Year-End 2025 Earnings Conference Call 2/26/2026 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. at 11:00 am Eastern Time on February 26, 2026 Today's Speakers St ...

– Training will consist of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart failure patients –TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On Training ...

forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, man ufa cturing developmen ...

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company’s board with complementary expertise in public company leadership, capital markets, and medical device commercialization. “These appointments reflect our cont ...

- Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch- Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided a ...

PROCEPT BioRobotics Corp. (NASDAQ:PRCT) shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance.Performance MetricsIn its fourth quarter of 2025, PROCEPT BioRobotics reported total revenue of $76.4 million, marking a 12% increase compared to the prior year, missing the consensus of $94.14 million. The increase was primarily driven by increased handpiece revenue.U.S. handpiece and consumable revenue was $34.0 million, an increas ...

LMAT Investor Presentation Disclaimers Unaudited Financial Results The quarterly financial results in this document are unaudited. Large and Growing Global Sales Force Forward-Looking Statements This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward- looking statements. Factors that might cau ...

Core Viewpoint - Enovis Corporation reported its financial results for Q4 and the full year of 2025, highlighting a net sales growth but significant losses due to goodwill impairment charges. Financial Results Summary Fourth Quarter 2025 - Net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for the year amounted to $2.2 billion, marking a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, which included a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the full year was reported at $403 million [6] Management Commentary - The CEO of Enovis stated that 2025 was a year of meaningful operational progress, with advancements in integration priorities and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it moves into 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, reflecting 4-6% organic revenue growth [8] - Adjusted EBITDA is anticipated to be between $425 million and $435 million, with adjusted earnings per share projected to be between $3.52 and $3.73 [8]

Core Viewpoint Enovis Corporation reported its financial results for the fourth quarter and full year of 2025, highlighting a mixed performance with a notable net loss primarily due to a significant goodwill impairment charge, while also indicating growth in net sales and expectations for 2026. Financial Results Summary Fourth Quarter 2025 - Enovis' net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for 2025 were $2.2 billion, representing a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, including a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the year was $403 million, with adjusted earnings per diluted share of $3.30 [6] Management Commentary - The CEO of Enovis stated that the performance in 2025 reflects meaningful operational progress, effective operations in a dynamic environment, and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it prepares for sustainable growth in 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, indicating 4-6% organic revenue growth [8] - Adjusted EBITDA is projected to be between $425 million and $435 million, with adjusted earnings per share expected to range from $3.52 to $3.73 [8]

This story was originally published on Cybersecurity Dive. To receive daily news and insights, subscribe to our free daily Cybersecurity Dive newsletter. UFP Technologies, a Massachusetts-based medical device maker, said it is investigating a cyberattack in mid-February that led to some of its company data being stolen or potentially destroyed, according to a regulatory filing.  The company said the attack, which was detected Feb. 14, impacted most of its IT network, as well as its billing and label-makin ...